<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>The Miller Lab</title>
    <link>/authors/admin/</link>
      <atom:link href="/authors/admin/index.xml" rel="self" type="application/rss+xml" />
    <description>The Miller Lab</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sat, 18 Jan 2020 11:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/MLab_logo_5.png</url>
      <title>The Miller Lab</title>
      <link>/authors/admin/</link>
    </image>
    
    <item>
      <title>Therapeutic Updates in Melanoma - IO for Earlier Stage Disease</title>
      <link>/talk/odac_melanoma-1-18-20/</link>
      <pubDate>Sat, 18 Jan 2020 11:00:00 +0000</pubDate>
      <guid>/talk/odac_melanoma-1-18-20/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma- Current Concepts in Diagnosis and Management</title>
      <link>/talk/odac_mcc-1-17-20/</link>
      <pubDate>Fri, 17 Jan 2020 15:35:00 +0000</pubDate>
      <guid>/talk/odac_mcc-1-17-20/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Evolving Landscape of Regulatory Medicine in Cutaneous Oncology</title>
      <link>/talk/cumc_derm_lecture_regulatory_medicine-12-13-19/</link>
      <pubDate>Fri, 13 Dec 2019 13:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_regulatory_medicine-12-13-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma - Pathogenesis, Clinical Features, Diagnosis and Management</title>
      <link>/talk/cumc_derm_lecture_melanoma-12-13-19/</link>
      <pubDate>Fri, 13 Dec 2019 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_melanoma-12-13-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management</title>
      <link>/slides/odac_mcc-1-17-20/</link>
      <pubDate>Mon, 09 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/odac_mcc-1-17-20/</guid>
      <description>
&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Disclosures.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Learning-Objectives.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Melanoma-Approvals.pdf&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Therapeutic Updates in Melanoma - IO for Earlier Stage Disease</title>
      <link>/slides/odac_melanoma-1-18-20/</link>
      <pubDate>Mon, 09 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/odac_melanoma-1-18-20/</guid>
      <description>
&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Disclosures.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Learning-Objectives.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Melanoma-Approvals.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Targeted-Therapy.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Immune-Checkpoints.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Melanoma-Approvals-Color.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Pilot-Study.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Instruments.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Pilot-Part-1.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Data-Collection.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Next-Steps.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Acknowledgements.pdf&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Evolving Landscape of Regulatory Medicine in Cutaneous Oncology</title>
      <link>/slides/reg_med_cut_onc-12-13-19-primer/</link>
      <pubDate>Sun, 08 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/reg_med_cut_onc-12-13-19-primer/</guid>
      <description>


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.pdf&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;learning-objective&#34;&gt;Learning Objective&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Overview of Regulatory Medicine&lt;/li&gt;
&lt;li&gt;Evalutino of FDA Action in Cutaneous Oncology&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Hx-FDA.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/PDUFA-Hx.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Clinical-Benefit.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Trial-Endpoints.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Approval_Pathways.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Levels-of-Clinical-Evidence.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Internal-External-Validity.pdf&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Melanoma - Pathogenesis, Diagnosis and Work Up</title>
      <link>/slides/melanoma_12_13_19-primer/</link>
      <pubDate>Sun, 08 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/melanoma_12_13_19-primer/</guid>
      <description>


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.pdf&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;learning-objective&#34;&gt;Learning Objective&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Review basic epidemiology of melanoma&lt;/li&gt;
&lt;li&gt;Review molecular mechanisms of melanoma&lt;/li&gt;
&lt;li&gt;Discuss risk factors for melanoma&lt;/li&gt;
&lt;li&gt;Review how to evaluate and stage patients&lt;/li&gt;
&lt;li&gt;Overview of management of melanoma&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;epidemiology&#34;&gt;Epidemiology&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;1:25 Americans will get some kind of melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;1:52 Americans will get an invasive melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;Estimated to be 96,480 newly diagnosed cases of invasive melanoma in the U.S. in 2019

&lt;ul&gt;
&lt;li&gt;95,830 cases of melanoma in situ&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;Between 9,000-10,000 deaths annually&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;pathogenesis&#34;&gt;Pathogenesis&lt;/h2&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways-legend.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/cell-cycle.pdf&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-cycle-cycle-figure&#34;&gt;Legend for Cycle Cycle Figure&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;The cell cycle is regulated by the dynamic interactions of highly coordinated enzymatic proteins to ensure genomic fidelity.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-cycle-cycle-figure-cont&#34;&gt;Legend for Cycle Cycle Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Cells first enter the cell cycle after receiving mitogenic signals, from stimuli such as RAS, which activate the cyclin D-dependent kinases, CDK4 and CDK6, via increased expression of cyclin D and by triggering release from inhibitory INK4 (p15 and p16) and CIP/KIP (p21CIP1 and p27KIP1) proteins.
&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-cycle-cycle-figure-cont-1&#34;&gt;Legend for Cycle Cycle Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Early in G1, RB is initially phosphorylated by cyclin Dâ€“CDK4/6 complexes, which abrogates the RB-dependent inhibition of the transcription factor E2F.&lt;/li&gt;
&lt;li&gt;E2F transcription factors are then released from the partially phosphorylated RB and promote transcription of genes (e.g. CCNE1) necessary to progress through the G1/S checkpoint.&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-cycle-cycle-figure-cont-2&#34;&gt;Legend for Cycle Cycle Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;RB is further phosphorylated in late G1 by cyclin Eâ€“CDK2 complexes, enabling E2F transcription factors to express genes required for DNA synthesis. After entry into the S phase, a hyperphosphorylated state of RB is maintained by the activities of cyclin Aâ€“CDK2, cyclin Aâ€“CDK1 and cyclin Bâ€“CDK1 complexes.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-cycle-cycle-figure-cont-3&#34;&gt;Legend for Cycle Cycle Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;At the end of mitosis RB proteins are dephosphorylated by phosphatases allowing recombination with E2F and DP to prevent unregulated cell proliferation. The cell cycle is negatively regulated by members of the INK4 (p15, p16) and CIP/KIP families (p21CIP1 and p27KIP1)&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;citation&#34;&gt;Citation&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Legend for Cycle-Cycle Figure is from: Miller DM, Flaherty KT. Pigment Cell Melanoma Research. 2014 May;27(3):351-65&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/senescence.pdf&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-senescence-pathways-figure&#34;&gt;Legend For Senescence Pathways Figure&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;The cellular senescence program can be initiated via several pathway outputs that utilize common effector molecules.&lt;br /&gt;&lt;/li&gt;
&lt;li&gt;While the mechanisms governing senescence have yet to be fully described, telomere shortening is believed to trigger cellular arrest by activating INK4a-RB signaling and the p53-p21 pathway via molecules such as ATM, ATR and CHK2.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-senescence-pathways-figure-cont&#34;&gt;Legend For Senescence Pathways Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Permanent inactivation of CDKs can also occur downstream of the DNA damage response (DDR), which can be triggered by a variety of genotoxic stimuli including ultraviolet (UV) radiation, reactive oxygen species (ROS) and hyper-replicative DNA (HRD).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-senescence-pathways-figure-cont-1&#34;&gt;Legend For Senescence Pathways Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;The DDR stimulates INK4a-mediated inhibition of CDK4/6 and the p53-p21 pathway in part via ARF inhibition of MDM2-mediated ubiquitination of p53 and activation of ATM.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-senescence-pathways-figure-cont-2&#34;&gt;Legend For Senescence Pathways Figure (Cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Activation of INK4a inhibits the CDK4/ 6-mediated activation of FOXM1, which antagonizes ROS-mediated DNA damage.&lt;br /&gt;&lt;/li&gt;
&lt;li&gt;The senescence cascade is also activated in certain contexts of persistent mitogenic stimulation, such as constitutive activation of RAS or RAF proteins (referred to as oncogene-induced senescence (OIS).&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-senescence-pathways-figure-cont-3&#34;&gt;Legend For Senescence Pathways Figure (Cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;OIS involves p38 MAPK and activates RB and p53 via HBP1 and PRAK, respectively&lt;br /&gt;&lt;/li&gt;
&lt;li&gt;Active RB contributes to formation of senescence-associated heterochromatin foci (SAHF), and this heterochromatization of DNA precludes transcription of E2F target genes, contributing to the overall state of irreversible cell-cycle arrest.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;citation-1&#34;&gt;Citation&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Legend for Cycle-Cycle Figure is from: Miller DM, Flaherty KT. Pigment Cell Melanoma Research. 2014 May;27(3):351-65&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h3 id=&#34;susceptibility-to-cutaneous-malignant-melanoma-cmm&#34;&gt;Susceptibility to Cutaneous Malignant Melanoma (CMM)&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;CMM1 has been mapped to chromosome 1p36.&lt;/li&gt;
&lt;li&gt;CMM2 â€“ CDKN2A (9p21)&lt;/li&gt;
&lt;li&gt;CMM3 â€“ CDK4 (12q14)&lt;/li&gt;
&lt;li&gt;CMM4 â€“ mapped to chromosome 1p22&lt;/li&gt;
&lt;li&gt;CMM5 â€“ MC1R (16q24)&lt;/li&gt;
&lt;li&gt;CMM6 â€“ XRCC3 (14q32)&lt;/li&gt;
&lt;li&gt;CMM7 â€“ mapped to chromosome 20q11&lt;/li&gt;
&lt;li&gt;CMM8 â€“ MITF (3p13)&lt;/li&gt;
&lt;li&gt;CMM9 â€“ TERT (5p15)&lt;/li&gt;
&lt;li&gt;CMM10 â€“ POT1 (7q31)&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CDKN2A.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Prognosis.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-strategies.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Approved-Tx.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CIT.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CIT-90.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CIT-100.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-immuntherapy-figure&#34;&gt;Legend for Immuntherapy Figure&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;T-cell activation results from the summation of several activating signals.&lt;/li&gt;
&lt;li&gt;These include stimulation of the T-cell receptor (TCR) by an antigen complexed with the major histocompatibility complex (MHC) and CD28 by CD80 or CD86 (CD80/86).&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-immuntherapy-figure-cont&#34;&gt;Legend for Immuntherapy Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Of note, MHC class I molecules activate CD8+-T cells, while MHC class II molecules are recognized by CD4+-T cells. T-cell activation and function are tightly calibrated by regulatory mechanisms to prevent autoimmunity and excessive tissue inflammation.&lt;/li&gt;
&lt;li&gt;T-cell activation is negatively regulated by CTLA4, which not only competes with CD28 for CD80 and CD86, but can also transmit inhibitory signals that attenuate activation.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-immuntherapy-figure-cont-1&#34;&gt;Legend for Immuntherapy Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;In peripheral tissues, ligation of the program death-1 (PD-1) receptor by PD-L1 inhibits effector functions of T-cells.&lt;/li&gt;
&lt;li&gt;PD-L1 is expressed on both antigen-presenting cells, such as macrophages, and malignant melanocytes.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;legend-for-immuntherapy-figure-cont-2&#34;&gt;Legend for Immuntherapy Figure (cont.)&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Monoclonal antibodies directed against CTLA-4 (ipilimumab), PD-1 (nivolumab and Pembrolizumab) and PD-L1 (Avelumab/Atezolizumb; of note, neither are approved for melanoma, but are approved for other malignancies) can overcome intrinsic immune checkpoints by licensing tumor-specific T cells.&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;citation-for-immuntherapy-figure&#34;&gt;Citation for Immuntherapy Figure&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Miller D,  Flaherty K, and Tsao H. Seminars in Cutaneous Medicine and Surgery, Vol. 33, June 2014&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Stage-3-Tx.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-Metastatic-Dz.pdf&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Project Data Sphere and Ongoing Multi-Institutional Database Efforts</title>
      <link>/slides/moffit-10-21-19/</link>
      <pubDate>Sun, 08 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/moffit-10-21-19/</guid>
      <description>
&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Disclosures.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Unmet-Need.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/PDS-MCC-Registry.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Task-Force.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Objectives-and-Applications.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/FDA-Guidance.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Pilot-Study.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Instruments.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Pilot-Part-1.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Data-Collection.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Next-Steps.pdf&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Acknowledgements.pdf&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Website Development With R</title>
      <link>/post/website-development-using-r/</link>
      <pubDate>Sat, 07 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/post/website-development-using-r/</guid>
      <description>

&lt;h2 id=&#34;overview&#34;&gt;Overview&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;This working document is a rough user guide on how to create a website using R via a package called &lt;code&gt;blogdown&lt;/code&gt;. It will also walk you through opening in account on Netlify, which will host your website.&lt;/li&gt;
&lt;li&gt;There are numerous resources for webpage development, including an amazing bookdown called &amp;ldquo;blogdown: Creating Websites with R Markdown&amp;rdquo; (&lt;a href=&#34;https://bookdown.org/yihui/blogdown/&#34; target=&#34;_blank&#34;&gt;https://bookdown.org/yihui/blogdown/&lt;/a&gt;). We&amp;rsquo;ve created this resource as we have tried to provide details and pearls that we struggled with and we belive these may be helpful to others.&lt;/li&gt;
&lt;li&gt;This is a ongoing, &amp;lsquo;living&amp;rsquo; document that is constantly being edited and expanded. Please provide comments to allow us to optimize this document for all R users.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&#34;please-see-the-attached-pdf-for-more-information&#34;&gt;Please see the attached PDF for more information.&lt;/h3&gt;

&lt;p&gt;&lt;a href=&#34;./Website_Development_in_R.pdf&#34;&gt;Website Development in R&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Cutaneous Oncology Research Fellow</title>
      <link>/post/cutaneous-oncology-research-fellow/</link>
      <pubDate>Fri, 06 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/post/cutaneous-oncology-research-fellow/</guid>
      <description>&lt;p&gt;The Massachusetts General Hospital Cancer Center and the Department of Dermatology are offering a 1-2 year research fellowship in cutaneous oncology. This position will provide a unique experience in cutaneous oncology and will include roles in clinical investigation and translational research.&lt;/p&gt;

&lt;p&gt;Please see the attached PDF for more information.&lt;/p&gt;

&lt;p&gt;&lt;a href=&#34;./CORF-post.pdf&#34;&gt;Cutaneous Oncology Research Fellow Posting&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Current Fellows&lt;/strong&gt;&lt;br /&gt;
- &lt;a href=&#34;https://www.themillerlab.io/authors/fellows/&#34; target=&#34;_blank&#34;&gt;Sophia Shalhout, PhD&lt;/a&gt;
&lt;img src=&#34;/img/SZS.png&#34; alt=&#34;png&#34; /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Clinical Investigation in cSCC - Updates from ASCO and ESMO</title>
      <link>/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/</link>
      <pubDate>Tue, 19 Nov 2019 07:00:00 +0000</pubDate>
      <guid>/talk/mgh_meei_nmsc_program_research_meeting-11_19_19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Project Data Sphere and Ongoing Multi-Institutional Database Efforts</title>
      <link>/talk/moffit_10-21-19/</link>
      <pubDate>Mon, 21 Oct 2019 16:30:00 +0000</pubDate>
      <guid>/talk/moffit_10-21-19/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;./featured_1.jpg&#34; alt=&#34;Dr. Miller presenting at MCC Symposium&#34; /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>2019 ASCO IO Abstracts Review</title>
      <link>/talk/sanofi_expert_series/</link>
      <pubDate>Mon, 07 Oct 2019 15:00:00 +0000</pubDate>
      <guid>/talk/sanofi_expert_series/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Project Data Sphereâ€™s Mentoring Award in Oncology, Advanced Analytics and Regulatory Science</title>
      <link>/funding/pds-award/</link>
      <pubDate>Sun, 01 Sep 2019 09:30:00 +0000</pubDate>
      <guid>/funding/pds-award/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;The Merkel Cell Carcinoma Patient Registry is a multi-institutional collaborative effort that is collecting data on outcomes and events in MCC patients. MCC is the prototypical rare tumor, and this Registry aims to develop new methodologies that will enable investigators to examine real world data in real time. Deliverables from the Registry include: (i) precise patient risk stratification, (ii) real-world data for drug development programs, (iii) identification of optimal sequence and combinations therapies, (iv) uncovering low-incidence toxicities and (v) revelations about best practices, (vi) and the generation of novel testable hypotheses.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Work Up and Management of Non-Melanoma Skin Cancer</title>
      <link>/talk/medical_education_program_on_melanoma_management_nmsc-8-23-19/</link>
      <pubDate>Fri, 23 Aug 2019 08:30:00 +0000</pubDate>
      <guid>/talk/medical_education_program_on_melanoma_management_nmsc-8-23-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Diagnosis and Initial Management of Melanoma</title>
      <link>/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/</link>
      <pubDate>Fri, 23 Aug 2019 08:00:00 +0000</pubDate>
      <guid>/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma</title>
      <link>/talk/harvard_derm_resident_lecture_melanoma-08-01-19/</link>
      <pubDate>Thu, 01 Aug 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_melanoma-08-01-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Project Data Sphere &amp; MCC patient Registry- From Promise to Prototype to Patient</title>
      <link>/talk/scout_6-2-19/</link>
      <pubDate>Sun, 02 Jun 2019 18:30:00 +0000</pubDate>
      <guid>/talk/scout_6-2-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Clinical and Translational Research in Cutaneous Oncology</title>
      <link>/talk/harvard_derm_interest_group-05-20-19/</link>
      <pubDate>Mon, 20 May 2019 18:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_interest_group-05-20-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cutaneous Oncology Board Preparation</title>
      <link>/talk/bidmc_board_prep-05-20-19/</link>
      <pubDate>Mon, 20 May 2019 15:00:00 +0000</pubDate>
      <guid>/talk/bidmc_board_prep-05-20-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Regulatory Medicine in Cutaneous Oncology</title>
      <link>/talk/unmc_5_7_19/</link>
      <pubDate>Tue, 07 May 2019 18:00:00 +0000</pubDate>
      <guid>/talk/unmc_5_7_19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma</title>
      <link>/talk/gw_derm_resident_lecture_mcc-04-18-19/</link>
      <pubDate>Thu, 18 Apr 2019 09:00:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_mcc-04-18-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Regulatory Medicine in Cutaneous Oncology</title>
      <link>/talk/mgh_cut_on_lect_series_reg_med-04_02_19/</link>
      <pubDate>Tue, 02 Apr 2019 09:00:00 +0000</pubDate>
      <guid>/talk/mgh_cut_on_lect_series_reg_med-04_02_19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Neoadjuvant PD-1 Blockade in Resectable Melanoma</title>
      <link>/talk/harvard_derm_resident_journal_club-03-25-19/</link>
      <pubDate>Mon, 25 Mar 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_journal_club-03-25-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Project Data Sphere &amp; MCC patient Registry- From Promise to Prototype to Patient</title>
      <link>/talk/mig_3-1-19/</link>
      <pubDate>Fri, 01 Mar 2019 18:00:00 +0000</pubDate>
      <guid>/talk/mig_3-1-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome Part 2 - Diagnosis and Management</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-02-22-19/</link>
      <pubDate>Fri, 22 Feb 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-02-22-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome Part 1 - Pathogenesis and Clinical Features</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-02-15-19/</link>
      <pubDate>Fri, 15 Feb 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-02-15-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-02-08-19/</link>
      <pubDate>Fri, 08 Feb 2019 07:45:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-02-08-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/gw_derm_resident_lecture_sezary-01-17-19/</link>
      <pubDate>Thu, 17 Jan 2019 14:30:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_sezary-01-17-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies of Dermatological Signficance</title>
      <link>/talk/gw_derm_resident_lecture_mgods-01-17-19/</link>
      <pubDate>Thu, 17 Jan 2019 13:00:00 +0000</pubDate>
      <guid>/talk/gw_derm_resident_lecture_mgods-01-17-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Clinical spectrum of cutaneous melanoma morphology.</title>
      <link>/publication/clinical-spectrum-of-melanoma/</link>
      <pubDate>Tue, 01 Jan 2019 00:00:00 +0000</pubDate>
      <guid>/publication/clinical-spectrum-of-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30165162&#34; target=&#34;_blank&#34;&gt;Clinical spectrum of cutaneous melanoma morphology.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Reducing M&amp;M in M&amp;M - Strategies to improve Morbidity and Mortality in Melanoma and Merkel cell carcinoma</title>
      <link>/talk/bidmc_hem_onc_grand_rounds_12_19-18/</link>
      <pubDate>Wed, 19 Dec 2018 08:30:00 +0000</pubDate>
      <guid>/talk/bidmc_hem_onc_grand_rounds_12_19-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>FDA Action in Cutaneous Oncology</title>
      <link>/talk/cumc_derm_lecture_regulatory_medicine-11-09-18/</link>
      <pubDate>Fri, 09 Nov 2018 13:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_regulatory_medicine-11-09-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/cumc_derm_lecture_sezary-11-09-18/</link>
      <pubDate>Fri, 09 Nov 2018 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_sezary-11-09-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Eczema Tvecium</title>
      <link>/publication/eczema-tvecium/</link>
      <pubDate>Thu, 01 Nov 2018 00:00:00 +0000</pubDate>
      <guid>/publication/eczema-tvecium/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/30454071&#34; target=&#34;_blank&#34;&gt;Kaposi&amp;rsquo;s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>PDS MCC Tumor Registry</title>
      <link>/talk/fda_registries_task_force-10-22-18/</link>
      <pubDate>Mon, 22 Oct 2018 12:00:00 +0000</pubDate>
      <guid>/talk/fda_registries_task_force-10-22-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PAMPs, DAMPs and Dermatology</title>
      <link>/talk/cumc_derm_lecture_innate_immunity-08-24-18/</link>
      <pubDate>Fri, 24 Aug 2018 11:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_innate_immunity-08-24-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>TCRs, Tsubs and dHSRs - T-cell Immunity for the Dermatologist</title>
      <link>/talk/cumc_derm_lecture_t_cell_biology-08-24-18/</link>
      <pubDate>Fri, 24 Aug 2018 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_t_cell_biology-08-24-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Introduction to Melanoma</title>
      <link>/talk/harvard_derm_resident_lecture_melanoma-07-31-18/</link>
      <pubDate>Tue, 31 Jul 2018 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_melanoma-07-31-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>ECOG ACRIN Paul Carbone, MD Fellowship Award</title>
      <link>/funding/ecog-acrin/</link>
      <pubDate>Sun, 01 Jul 2018 09:30:00 +0000</pubDate>
      <guid>/funding/ecog-acrin/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Role of CDK7 in Melanoma</title>
      <link>/publication/cdk7/</link>
      <pubDate>Sun, 01 Jul 2018 00:00:00 +0000</pubDate>
      <guid>/publication/cdk7/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/29408204&#34; target=&#34;_blank&#34;&gt;High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma - Updates in Diagnosis and Management</title>
      <link>/talk/meei_grand_rounds-06_14_18/</link>
      <pubDate>Thu, 14 Jun 2018 07:00:00 +0000</pubDate>
      <guid>/talk/meei_grand_rounds-06_14_18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma</title>
      <link>/talk/cumc_derm_lecture_mcc-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 13:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_mcc-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Biology of Cutaneous Oncology</title>
      <link>/talk/cumc_derm_lecture_cancer_biology-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 09:30:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_cancer_biology-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies of Dermatological Signficance</title>
      <link>/talk/cumc_derm_lecture_mgods-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 08:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_mgods-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PAMPs DAMPs and Dermatology - Innate Immunity for the Dermatologist</title>
      <link>/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/</link>
      <pubDate>Tue, 08 May 2018 09:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_innate_immunity-05-08-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>American Skin Association Research Grant</title>
      <link>/funding/asa/</link>
      <pubDate>Mon, 01 Jan 2018 09:30:00 +0000</pubDate>
      <guid>/funding/asa/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;Recent therapeutic advancements in melanoma have significantly improved the prognosis for thousands of patients with this life-threatening disease. Identification of key driver mutations in melanoma - such as BRAF - has led to the discovery of oncogene-directed therapies that have profoundly changed the therapeutic landscape in melanoma. Indeed, the development of small-molecule inhibitors of BRAF (e.g. vemurafenib and dabrafenib) and its downstream partner MEK (e.g trametinib and cobimetinib) established a new therapeutic paradigm in the management of melanoma. Nevertheless, despite these recent advancements, the prognosis for patients with metastatic disease remains poor, as resistance to these approaches emerges in the majority of patients. Thus, additional management options are sorely needed. This proposed research is designed to test the hypothesis that targeting the recently identified RNF125-JAK1-AXL/EGFR axis will overcome resistance to BRAF/MEK-targeted therapy. To test this hypothesis, we will conduct an investigator-initiated, Phase Ib/single-arm phase II expansion study with the novel JAK1 inhibitor INCB039110 (INCB) in patients with metastatic BRAF-mutant melanoma co-administered with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. We will also perform correlative studies using novel single-cell resolving technologies on pre- and post-treatment specimens to characterize the effects of targeting the RNF125-JAK1-AXL/EGFR axis on the tumor and its ecosystem in order to identify molecular and cellular determinants of resistance.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-12-19-17/</link>
      <pubDate>Tue, 19 Dec 2017 09:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-12-19-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>No Claims No Gains - Why You Need to Know the Business Side of Medicine</title>
      <link>/talk/bidmc_topics_in_oncology-12_14-17/</link>
      <pubDate>Thu, 14 Dec 2017 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_topics_in_oncology-12_14-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-11-21-17/</link>
      <pubDate>Tue, 21 Nov 2017 10:30:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-11-21-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Nivolumab as Adjuvant Therapy for Melanoma</title>
      <link>/talk/bidmc_journal_club_10-31-17/</link>
      <pubDate>Tue, 31 Oct 2017 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_journal_club_10-31-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A Complete Response in cSCC with Ipi/Nivo</title>
      <link>/publication/cr-ipi-nivo-scc/</link>
      <pubDate>Fri, 08 Sep 2017 00:00:00 +0000</pubDate>
      <guid>/publication/cr-ipi-nivo-scc/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/28932782&#34; target=&#34;_blank&#34;&gt;Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Sezary Syndrome</title>
      <link>/talk/harvard_derm_resident_lecture_sezary-05-30-17/</link>
      <pubDate>Tue, 30 May 2017 11:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_sezary-05-30-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Somatic Driver Mutations in Melanoma</title>
      <link>/publication/somatic-drivers-melanoma/</link>
      <pubDate>Fri, 19 May 2017 00:00:00 +0000</pubDate>
      <guid>/publication/somatic-drivers-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.30593&#34; target=&#34;_blank&#34;&gt;Somatic driver mutations in melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Avelumab for Patients with Merkel Cell Carcinoma</title>
      <link>/talk/bidmc_journal_club_05-02-17/</link>
      <pubDate>Tue, 02 May 2017 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_journal_club_05-02-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>mGODS - Monoclonal Gammopathies Of Dermatological Significance</title>
      <link>/talk/harvard_derm_resident_mgods-01-31-17/</link>
      <pubDate>Tue, 31 Jan 2017 10:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_mgods-01-31-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A novel multi-CDK inhibitor in Melanoma</title>
      <link>/publication/multi-cdk-inhibitor-in-melanoma/</link>
      <pubDate>Sat, 02 Jul 2016 00:00:00 +0000</pubDate>
      <guid>/publication/multi-cdk-inhibitor-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/26810603&#34; target=&#34;_blank&#34;&gt;A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Scratching the Surface of Acute Graft vs. Host Disease</title>
      <link>/talk/bidmc_hematology_gvhd-06_10-16/</link>
      <pubDate>Fri, 10 Jun 2016 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_hematology_gvhd-06_10-16/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Molecularly Targeted Therapies and Immunotherapies For Melanoma</title>
      <link>/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/</link>
      <pubDate>Wed, 01 Jun 2016 00:00:00 +0000</pubDate>
      <guid>/publication/review-of-molecularly-targeted-therapies-and-immunotherapies-for-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/25085663&#34; target=&#34;_blank&#34;&gt;Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>CDKs as Therapeutic Targets in Melanoma</title>
      <link>/publication/cdk-inhibotrs-in-melanoma/</link>
      <pubDate>Tue, 17 May 2016 00:00:00 +0000</pubDate>
      <guid>/publication/cdk-inhibotrs-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24405945&#34; target=&#34;_blank&#34;&gt;Cyclin-dependent kinases as therapeutic targets in melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Molecular testing in melanoma</title>
      <link>/publication/molecular-testing-in-melanoma/</link>
      <pubDate>Sun, 01 May 2016 00:00:00 +0000</pubDate>
      <guid>/publication/molecular-testing-in-melanoma/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/24534656&#34; target=&#34;_blank&#34;&gt;Commentary: Molecular Testing in Melanoma.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Approach to Purpura</title>
      <link>/talk/bwh_derm_directive_approach_to_purpura-03-25-16/</link>
      <pubDate>Fri, 25 Mar 2016 15:30:00 +0000</pubDate>
      <guid>/talk/bwh_derm_directive_approach_to_purpura-03-25-16/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Red Leg</title>
      <link>/talk/bwh_derm_directive_red_leg-01-29-16/</link>
      <pubDate>Fri, 29 Jan 2016 15:30:00 +0000</pubDate>
      <guid>/talk/bwh_derm_directive_red_leg-01-29-16/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Mycosis Fungoides - Clinical Features, Diagnosis &amp; Management</title>
      <link>/talk/bidmc_hematology_mf-01-15-16/</link>
      <pubDate>Fri, 15 Jan 2016 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_hematology_mf-01-15-16/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Common Primary Care Dermatoses</title>
      <link>/talk/bwh_im_amb_lecture_common_prim_care_derm-12-08-2017/</link>
      <pubDate>Tue, 08 Dec 2015 09:00:00 +0000</pubDate>
      <guid>/talk/bwh_im_amb_lecture_common_prim_care_derm-12-08-2017/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Merkel Cell Carcinoma</title>
      <link>/talk/bidmc_topics_in_oncology-12_03-15/</link>
      <pubDate>Thu, 03 Dec 2015 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_topics_in_oncology-12_03-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cellulitis and Its Mimics</title>
      <link>/talk/bwh_derm_directive_cellulitis_and_its_mimics-11-06-15/</link>
      <pubDate>Fri, 06 Nov 2015 15:30:00 +0000</pubDate>
      <guid>/talk/bwh_derm_directive_cellulitis_and_its_mimics-11-06-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Vesiculobullous Eruptions</title>
      <link>/talk/bwh_derm_directive_vesiculobullous_eruptions-10-09-15/</link>
      <pubDate>Fri, 09 Oct 2015 15:30:00 +0000</pubDate>
      <guid>/talk/bwh_derm_directive_vesiculobullous_eruptions-10-09-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Common Primary Care Dermatoses</title>
      <link>/talk/bwh_im_amb_lecture_common_prim_care_derm-10-06-2017/</link>
      <pubDate>Tue, 06 Oct 2015 09:00:00 +0000</pubDate>
      <guid>/talk/bwh_im_amb_lecture_common_prim_care_derm-10-06-2017/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Common Primary Care Dermatoses</title>
      <link>/talk/bwh_im_amb_lecture_common_prim_care_derm-09-22-2017/</link>
      <pubDate>Tue, 22 Sep 2015 09:00:00 +0000</pubDate>
      <guid>/talk/bwh_im_amb_lecture_common_prim_care_derm-09-22-2017/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma</title>
      <link>/talk/cumc_derm_lecture_melanoma-03-27-15/</link>
      <pubDate>Fri, 27 Mar 2015 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_melanoma-03-27-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Biology of Keratinocytes</title>
      <link>/talk/cumc_derm_lecture_keratinocyte_biology-01-28-15/</link>
      <pubDate>Wed, 28 Jan 2015 15:30:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_keratinocyte_biology-01-28-15/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Parameters for Establishing Humanized Mouse Models</title>
      <link>/publication/parameters-for-establishing-humanized-mouse-models/</link>
      <pubDate>Thu, 01 Apr 2010 00:00:00 +0000</pubDate>
      <guid>/publication/parameters-for-establishing-humanized-mouse-models/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/20096637&#34; target=&#34;_blank&#34;&gt;Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>TLR Activation Abrogates Mixed Chimerism</title>
      <link>/publication/tlr-agonists-abrogate-mixed-chimerism/</link>
      <pubDate>Mon, 01 Dec 2008 00:00:00 +0000</pubDate>
      <guid>/publication/tlr-agonists-abrogate-mixed-chimerism/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19120285&#34; target=&#34;_blank&#34;&gt;TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Viral infection - a potent barrier to transplantation tolerance</title>
      <link>/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/</link>
      <pubDate>Thu, 26 Jun 2008 00:00:00 +0000</pubDate>
      <guid>/publication/viral-infection-a-potent-barier-to-transplantation-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/18815618&#34; target=&#34;_blank&#34;&gt;Viral infection: a potent barrier to transplantation tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>TLR Agonists Abrogate Immunological Tolerance</title>
      <link>/publication/tlr-agonists-abrogate-immune-tolerance/</link>
      <pubDate>Thu, 01 May 2008 00:00:00 +0000</pubDate>
      <guid>/publication/tlr-agonists-abrogate-immune-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19380803&#34; target=&#34;_blank&#34;&gt;TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Role of Innate Immunity in Transplantation Tolerance</title>
      <link>/publication/role-of-innate-immunity-in-transplantation-tolerance/</link>
      <pubDate>Tue, 01 Apr 2008 00:00:00 +0000</pubDate>
      <guid>/publication/role-of-innate-immunity-in-transplantation-tolerance/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/19166387&#34; target=&#34;_blank&#34;&gt;Role of Innate Immunity in Transplantation Tolerance.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Different mechanisms control peripheral and central tolerance</title>
      <link>/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/</link>
      <pubDate>Sat, 09 Jun 2007 00:00:00 +0000</pubDate>
      <guid>/publication/different-mechanisms-control-peripheral-and-central-tolerance-in-hematopoietic-chimeric-mice/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/17564635&#34; target=&#34;_blank&#34;&gt;Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>American Diabetes Association Physician Scientist Training Award</title>
      <link>/funding/ada-fellowship/</link>
      <pubDate>Fri, 01 Jul 2005 09:30:00 +0000</pubDate>
      <guid>/funding/ada-fellowship/</guid>
      <description>

&lt;h1 id=&#34;overview&#34;&gt;Overview&lt;/h1&gt;

&lt;p&gt;The objective of this research was to investigate the ability of mesenchymal stem cells (MSCs), isolated from human bone marrow and human umbilical cord blood, to be used as cellular therapy for diabetes mellitus&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Jellypin -  a lower eukaryotic serine proteinase inhibitor (serpin)</title>
      <link>/publication/jellypin/</link>
      <pubDate>Tue, 21 Sep 2004 00:00:00 +0000</pubDate>
      <guid>/publication/jellypin/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/15362859&#34; target=&#34;_blank&#34;&gt;Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>The Serpin SQN-5</title>
      <link>/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/</link>
      <pubDate>Tue, 05 Mar 2002 00:00:00 +0000</pubDate>
      <guid>/publication/the-serpin-sqn-5-is-a-dual-mechanistic-class-inhibitor-of-serine-and-cysteine-proteinases/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.ncbi.nlm.nih.gov/pubmed/11863458&#34; target=&#34;_blank&#34;&gt;The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases.&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
